Predictive Oncology Inc. (POAI)

NASDAQ: POAI · IEX Real-Time Price · USD
0.410
-0.025 (-5.77%)
Aug 16, 2022 11:21 AM EDT - Market open
-5.77%
Market Cap 32.88M
Revenue (ttm) 1.48M
Net Income (ttm) -26.96M
Shares Out 80.19M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 90,395
Open 0.429
Previous Close 0.435
Day's Range 0.410 - 0.443
52-Week Range 0.249 - 1.466
Beta 1.36
Analysts Buy
Price Target 5.46 (+1,231.7%)
Earnings Date Aug 9, 2022

About POAI

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, a... [Read more...]

Industry Health Care Equipment & Supplies
Founded 2002
CEO Carl Schwartz
Employees 30
Stock Exchange NASDAQ
Ticker Symbol POAI
Full Company Profile

Financial Performance

In 2021, POAI's revenue was $1.42 million, an increase of 13.45% compared to the previous year's $1.25 million. Losses were -$19.66 million, -24.06% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for POAI stock is "Buy." The 12-month stock price forecast is 5.46, which is an increase of 1,231.71% from the latest price.

Price Target
$5.46
(1,231.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Predictive Oncology Reports Second Quarter 2022 Financial Results

EAGAN, Minn., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022, which shows a strong balance she...

Traders News Source Senior Editor Mark Roberts Interviews J. Melville Engle, CEO and Chairman of the Board, Predictiv...

NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a...

Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansi...

EAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner,...

Predictive Oncology Announces Closing of $7.2 Million Registered Direct Offerings

EAGAN, Minn., May 18, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...

Predictive Oncology Announces $7.2 Million Registered Direct Offerings

EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...

Predictive Oncology Reports First Quarter Financial Results

EAGAN, Minn., May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predi...

Marketer with over 20 years of experience selected to head up marketing at Predictive Oncology

EAGAN, Minn., April 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director of Marketing. As Predictive Oncology's senior mar...

Predictive Oncology Reports Year End 2021 Financial Results and Provides Business Update

EAGAN, Minn., March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug disco...

Predictive Oncology validates Discovery 21 proof-of-concept campaign

Predictive Oncology's Discovery 21 campaign evaluated the ability of its PeDAL® platform to make high-confidence predictions in ovarian tumor samples. Subsequent validation confirmed the accuracy and re...

Predictive Oncology set to market AI drug discovery platform

MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will...

POAI Reports Strong Results From Its AI Cancer Drug Evaluation

MINNEAPOLIS, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary's eva...

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021

MINNEAPOLIS, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...

Predictive Oncology Inc. (POAI) Upgraded to Buy: What Does It Mean for the Stock?

Predictive Oncology Inc. (POAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Predictive Oncology – Year-end Shareholder Update!

EAGAN, Minn., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is mov...

Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business Development

Bush to lead Predictive Oncology's novel sales effort towards cancer research technologies Bush to lead Predictive Oncology's novel sales effort towards cancer research technologies

Predictive Oncology Acquires zPREDICTA, Inc.

zPREDICTA has developed a patented tumor-specific 3D cell culture platform that is complementary to Predictive Oncology's Artificial Intelligence (AI) platform developed by Helomics. zPREDICTA's uniquel...

Predictive Oncology Inc. (POAI) Reports Q3 Loss, Misses Revenue Estimates

Predictive Oncology Inc. (POAI) delivered earnings and revenue surprises of 20.00% and -82.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

Predictive Oncology Reports Third Quarter Financial Results

EAGAN, Minn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Results from the third quarter show strong potential for future growth, said Predictive Oncology (Nasdaq: POAI) today, announcing financial results for th...

Predictive Oncology Inc. (POAI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Predictive Oncology Inc. (POAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements

Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research Predictive Oncology is leveraging AI t...

Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting

MINNEAPOLIS, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...

Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...

Predictive Oncology Adjourns Special Meeting of Stockholders

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...

Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer ...

Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. Ini...